Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Townsville’s First Ever Twilight Melanoma March

She will next month join Townsville’s first ever twilight Melanoma March in honour of her mother, Gina Sellen, who lost her battle against the deadly cancer in 2016.

Cancer in the News

Feature Articles

Study: Fat cells play key role in dangerous transformation of melanoma

Researchers at Tel Aviv University, led by Prof. Carmit Levy and Dr. Tamar Golan of the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine, have discovered that fat cells are involved in the transformation that melanoma cells undergo from cancer cells of limited growth in the epidermis to lethal metastatic cells […]


Posted in Melanoma News, Health Professionals, Of Interest

Dr. Flaherty on the COLUMBUS Trial Updates in BRAF-Mutant Melanoma

Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses an update on overall survival (OS) in COLUMBUS, a randomized phase III trial of encorafenib (Braftovi) plus binimetinib (Mektovi) versus vemurafenib (Zelboraf) or encorafenib in patients with BRAF V600-mutant melanoma.


Posted in Melanoma News, Health Professionals, Of Interest

Melanoma: Optimizing Selection of Adjuvant Therapy

Dirk Schadendorf, MD, PhD: I disagree. I think what we have to keep in mind that in stage III disease, with just the surgery we are curing, is in roughly one-third of the patients.


Posted in Melanoma News, Health Professionals, Of Interest

Dr. Long on Dabrafenib/Trametinib in BRAF V600E-Mutant Melanoma

Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses results from the 5-year analysis of the combination of dabrafenib and trametinib in patients with BRAF V600E-mutant melanoma.


Posted in Melanoma News, Health Professionals, Video Reports